A manufacturer-funded cost-effectiveness model found the MiniMed 780G closed-loop system cost-effective versus injections with isCGM in US type 1 diabetes at $100,000 per QALY (ICER $68,402 over 4 years, $38,842 lifetime). PICO summary and expert commentary.
Browsing: Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
A phase 3 open-label trial in 440 Chinese adults found the dulaglutide biosimilar LY05008 met its equivalence margin for HbA1c reduction against reference dulaglutide. PICO summary and expert commentary.
A small mechanistic RCT (n=34) found ertugliflozin did not increase proximal tubular natriuresis (the primary outcome) but did reduce fluid volume and blood pressure by week 12. PICO summary and expert commentary.
A small open-label Spanish RCT found a digital education program added to GLP-1 therapy produced greater HbA1c, weight, and adherence gains than usual care over six months. PICO summary and expert commentary.
A small open-label randomised trial comparing dapagliflozin with insulin glargine as a fourth agent for glycaemic variability in type 2 diabetes inadequately controlled on triple therapy. PICO summary and expert commentary.
A small randomized trial compared perindopril plus indapamide against perindopril plus moxonidine (both with metformin) for left ventricular and renal protection in hypertension with prediabetes. PICO summary and expert commentary.
In 22,220 older US adults, daily vitamin D did not significantly reduce incident type 2 diabetes, though a pooled meta-analysis hinted at a modest benefit. PICO summary and expert commentary.
A double-blind RCT in 67 children found Ringer’s lactate shortened time to DKA resolution versus 0.9% saline, with less hyperchloraemia. PICO summary and expert commentary.
A phase I/II randomized trial found long-term controlled-release oral GABA (Remygen) did not improve C-peptide, CGM metrics, or HbA1c in men with long-standing type 1 diabetes, and side effects were common. PICO summary and expert commentary.
A single-centre randomised trial of 200 women found metformin matched insulin for glycaemic control in gestational diabetes, with some neonatal outcomes favouring metformin. PICO summary and expert commentary.